DOCSLIB.ORG

Index Vol. 16-23

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

233 Index Vol. 16-23 The references of the Subject Index are given in the language of the respective contribution. Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgeftihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. A 17 Abortion, therapeutic 457,460 23 Acetylsalicylic acid (Aspirin®) 114 20 Academic research 169 16 O-Acetylserin-Sulfhydrylase A 390 18 Acanthocheilonema perstans 142 17 Acetylstrophanthidin 35 18 Acanthocheilonema streptocerca 142 22 Achromycin® (tetracycline) 53 22 Acaprin® (quinuronium sulfate) 42 19 Acidosis 529 20 Acebutolol 33, 36, 229 18 Acid phosphotase 66 18 Acedapson (Hansolar®, 4',4"'-sulfonylbis­ 16 Aconitase-Isomerase 436 acetanilide) 108, 156 17 Aconitine 35,46 17 Acedist® (bromfenofos, Ph 1882) 113, 134, 17 Acranil 119, 152 278 17 Acrichine® (quinacrine) 119 18 Aceperone 437 17 Acridine 295 16 Acetacetat-Decarboxylase 414 16 Acriftavin 100 17 2-Acetamido-5-nitrothiazole 261 17 Acrolein 358 17 Acetanilide 23, 497 18 Acronine 440 20 Acetanilide 400 21 Acrosin 366 23 Acetanilide 212 21 Acrylamide 186 20 Acetazolamide (Diamox®) 209,417 17 Actamer® (bithionol) 114,297 21 - 114 22 Actamer® (bithionol) 46 22 Acetohexamide (Dymelor®) 81 16 Actinomycin I 298 17 Acetohydroxamic acid 348 16 Actinomycin IV 298 17 Acetone 13, 17 16 Actinomycin V 298 16 Acetophenone 260 17 Actinomycin C, (actinomycin D) 376 17 2-Acetoxy-4' -chloro-3,5-diiodobenzanilide 16 Actinomycin D (actinomycin C" (clioxanide) 114,135,164,277,281 dactinomycin) 89, 118 17 a-Acetoxyheptanoic acid 416 17 - 273,302,376 17 7-Acetoxy-4-oxo-dodecanoic acid 416 20 - 467,474 16 4-Acetylaminobenzenesulfonamide 254 21 - 199 16 3-Acetylaminophenanthrene 259 22 - 132 16 2-Acetylamino-4-phenylthiazole 259 23 - 38 16 4-Acetylaminopropiophenone 254 22 Aculeacin A 131 22 Acetylaranotin 309 21 Acute toxicity 212 16 Acetylcholine 219,335,340 23 N-Acyl-L-amino acid esters 141, 152 17 Acetylcholine 46 20 5'-O-Acyl-ara-cytidines 588 19 Acetylcholine 148 16 Acyl hydroxylation 231 20 Acetylcholine 335, 410 17 I-Acyl-3-(2-thiocarbamoyl-5- 20 Acetylcholine receptor 335 thiazolyl)urease 262 20 Acetylcholine receptor function 337 20 Adalat® (nifedipin) 407 20 Acetylcholine receptor isolation 336 22 Adamantane derivatives 277 16 Acetylcholinesterase 219,336,370,410 19 Adenine 468 20 Acetylcholinesterase 108, 324 21 Adenocarcinoma 243 16 Acetylcholinesterase activity 355 19 cyclic-Adenosine monophosphate 16 Acetylcholinesterases inhibitors 170 (adenosine 3',5'-monophosphate, cyclic­ 16 Acetyl Co-A-Carboxylase 420 AMP) 511 20 N-Acetylcysteine 480 20 - 272,329 16 N-Acetylmuramyl-I-alanine amidase 328 23 - 43 22 N-Acetylneuraminic acid 307 16 Adenosin-Desaminase 408 20 Acetylsalicylic acid (Aspirin®) 400 16 Adenosintriphosphatase 412,414,438 234 Index Vol. 16-23 17 Adenosinetriphosphatase 299 20 Aldophosphamide 468 17 Adenosine triphosphate (ATP) 62 16 Aldose-Reductase 390 19 Adenosine triphosphate (ATP) 511 22 Aldosterone (Aldocorteneill» 68, 76 20 Adenosine triphosphate (ATP) 272 20 Aldosterone antagonists 213 16 AdenosyJmethionin-Decarboxylase 396 16 Alfalfa Mosaikvirus 384 19 Adenovirus 280 16 ALG (Antilymphocyte globulin) 102, 123 20 Adenylate cyclase 329 18 Alkaloids 409 21 Adenylate cyclase 412,414 22 Alkeranill> (melphalan) 63 16 Adenylat-Kinase 390 16 Alkohol-Dehydrogenase 388,392,400 19 Adenylcyclase 511,567 23 Alkylammonium compounds 120 20 Adenylcyclase 274 17 2-Alkyl-I,2,3,3a,4,5- 16 Adenyl-Succinase 406 hexahydroimidazo[l,5-a]quinolines 254 20 Adiphenine (Trasentineill» 420 16 N-(3-Alkyl-5-nitro-4-thiazolin-2- 20 Adrenaline 410,418 ylidene)amides 19,20 20 a-Adrenergic blockers 199 22 N-Alkylnorpethidines 169 19 p-Adrenergic blockers 361 23 N-Alkylpiperidines 171 20 p-Adrenergic blockers 222 23 4-Alkylpyridines 103 20 p-Adrenergic receptor 340 23 N-Alkylpyridinium compounds 171 16 Adrenocortical microsomes 262 23 N-n-Alkyltritylamines 122 17 Adriamycin 374 23 Allamandin 83 18 Adriamycin 441 16 Allanosine 90 20 Adriamycin 467, 474 17 Allantoin 340 22 Adriamycin 67 20 Allercurill> (clemizole) 426 18 Adriamycinone 441 20 Allergen 589 18 Aedes aegypti 284 18 Allergic reaction 255 18 Aedes polynesiensis 264 20 Allergic rhinitis 589 17 A elurostrongylus abstrusus 178 18 Allobarbital 453 21 AF 1890 [1-(2,4-dichlorobenzyl)-indazole- 19 Allobarbitone 210,225 3-carboxylic acid] 354 17 Allopurinol (Zyloprimill» 340 21 AF 1312/TS (I-p-chlorobenzyl-IH- 20 - 402 indazole-3-carboxylic acid) 353 17 Allylthiourea (thiosinamine) 274 20 Affinity constants 136 22 Alpenill> (ampicillin) 50 20 African trypanosomiasis 445 22 Alphaprodine (Nisentilill» 172 22 Afridol violet 38 22 Alprazolam 254, 255 16 Ag-Ab (Antigen-antibody complex) liS 16 Alprenolol 355 19 Agglutination test 179,556 20 Alprenolol 33, 36, 226, 229, 230 23 Agglutination test 17 20 p-Alprenolol 227 20 Agglutinin 328 16 ALS (Antilymphocyte serum) 101 23 Agglutinin 16 22 Altafurlll> (furaltadone) 45 23 Agglutinogens 21 19 Aluminium hydroxide 613,618 23 AIPF (anaphylactoid inflammation 23 Aluminium hydroxide IS promoting factor) 38 19 Aluminium phosphate 265 16 Alanyl-tRNA-Synthetase 400 20 Alupentill> (orciprenaline) 419 17 Alazopeptin 324 16 Amantadine (Symmetrelill» 347 22 Albegoill> (camazepam) 242 20 - 423 22 Albucidill> (sulfacetamide) 31 22 - 62.277 17 Alcohol 94 16 Ambilharlll> (niridazole) 14 17 Alcoparill> (bephenium 20 Ambilharill> (niridazole) 448 hydroxynaphthoate) 130 22 Ambilharill> (niridazole) 47 20 Alcoparill> (bephenium 17 Amebarsinill> (diphetarsone) 123 hydroxynaphthoate) 451 18 Amebic disease, pathogenesis 225 22 Alcoparlll> (bephenium 22 Amenoroneill> (ethisterone) 73 hydroxynaphthoate) 47 20 American trypanosomiasis (Chagas 22 Aldactoneill> (spironolactone) 76 Disease) 446 16 Aldehyde dehydrogenase 246,442 22 Amethopterinill> (methotrexate) 64 20 Alderinill> (pronethalol) 411 16 w -Amidase 388 22 Aldocorteneill> (aldosterone) 76 22 Amidines 299 16 Aldolase A 402 17 Amidostomum anseris 171 16 Aldolase B 402 20 Amidoximes 214 20 Aldometill> (a-methyldopa) 411 22 Amikacin (Amikinill>, Biklinill» 57 17 Aldophosphamide 357 22 Amikinill> (amikacin) 57 Index Vol. 16-23 235 20 Amiloride (Midamor®) 213,417 18 Amiperone 437 17 Amino acids 82 20 Amiphenazole (Daptazole®) 397 22 Amino acids 308 20 Amitriptyline (Elavil®, Laroxyl®) 394 16 4-Aminobenzenesulfonamide 16 Amitryptilinemethyliodate 352 (sulfanilamide) 259 18 Amodiaquine (Camoquin®) 102, 103, 143 19 p-Aminobenzoic acid 286 20 - 435 21 p-Aminobenzoic acid 191 22 - 42 17 6-Amino-2,4-bis(trichloromethyl)-1,3- 18 Amoebiasis 78,225,278,355 benzodioxan 286 19 Amoebiasis 570 16 y-Aminobutyric acid 221,222,290,339, 20 Amoebiasis 438 348 18 Amoebiasis, exfoliative 82 20 y-Aminobutyric acid receptor 341 18 Amoebiasis, surgical problems 79 16 e-Aminocaproic acid 88, 118 18 Amoebicidal drugs, evaluation 353 16 l-Aminocyclopentane carboxylic acid 20 Amoebicides 438 (cycloleucine) 88 18 Amoeboma 83 22 6-Amino-6-deoxy-o-glucose 307 17 Amoebotaenia sphenoides 299 17 4-Amino-4-deoxypteroic acid 325 18 Amopyroquine (Propoquin®) 102 22 5'-Amino-2',5'-dideoxy-5-iodouridine 296 22 Amoxicillin (Amoxil®) 50 17 2-Amino-5-( diethylamino )phenol 260 22 Amoxil® (amoxicillin) 50 17 2-Amino-4,7-dimethoxy-6- 20 cyclic-AMP (cyclic adenosine 3',5'­ thiocyanatobenzothiazole 272 monophosphate) 272,329,580,585 22 Aminoglutethimide (Elipten®) 77 21 - 414 22 2-Amino-4-hydroxypyrimidines 276 16 AMP (adenosin monophosphat) 17 5-Aminoimidazole-4-carboxamide 336, desaminase 410 338 16 AMP Nucleosidase 398 16 b-Aminolaevulinsllure-Dehydratase 440 16 Amphetamine (Benzedrine®) 217,341,346 18 2-Amino-5-( l-methyl-5-nitro-2-imid­ 20 - 397,418 azolyl)-1,3,4-thiadiazole 327 22 Amphetamine derivatives 363 17 4-Amino-2-methyl-N-(5-nitro-2-thiazolyl)- 16 d-Amphetamine 347 5-pyrimidinecarboxamide 262 16 I-Amphetamine 347 17 2-Aminomethyltetrahydroquinolines 252 18 Amphotericin B 290, 320 21 6-Aminonicotinamide 199 20 Amphotericin B 441,443,444 17 trans-5-Amino-3-[2-(5-nitro-2-furyl)vinyl]- 22 Amphotericin B 59, 97, 103, 132 1,2,4-oxadiazole (SQ 18506) 267 16 Ampicillin (Alpen®, Penbritin®, 17 6-Amino-N-(5-nitro-2-thiazolyl)-m- Polycillin®) 313 toluamide 263 19 - 539 16 Aminopeptidase 414 22 - 50 20 Aminophenazone (Pyramidon®) 401 20 Amplivix® (benziodarone) 407 17 N-(p-Aminophenyl)-N',N'- 20 Amprotropine (Syntropan®) 420 dimethylacetamidine 309 16 a-Amylase 388 16 Aminopterin 93, 118 16 p-Amylase 406 17 Aminopterin 324 20 Amylene hydrate 387 18 Aminopterin 107 22 Amylobarbitone 360 20 Aminopterin 471 16 iso-Amylphenylketone 262 22 6-Aminopyrazolo[4,3-c]pyridin-4(5H)- 22 Anadrol® (oxymetholone) 69 one 289 17 Anaemia, haemolytic 64 17 4-Aminopyrazolo[3,4-d]pyrimidine 343 20 Anaesthetics 386 17 7-Aminopyrazolo[4,3-d]pyrimidine 343 22 Analgesic antagonists 150 23 1-(3-Amino-4-pyridyl)-4-aryl- 22 Analgesics 150 piperazines 213 23 Anaphylactoid inflammation promoting 17 Aminopyrine 490 factor (AIPF) 38 17 4-Aminopyrrolo[2,3-d]pyrimidine 344 20 Anaphylaxis 589 18 4-Aminoquinolines 101, 104 22 Anavar® (oxandrolone) 70 18 p-Aminosalicylic acid (PAS) 212 17 Ancaris® (thenium) 130 22 p-Aminosalicylic acid (PAS) 34 22 Ancef® (cefazolin) 53 16 d-Aminosllure-Oxidase 396 22 Ancobon® (flucytosine) 36 16 I-Aminosllure-Oxidase 400 17 Ancylol® (disophenol) 131 21 Aminosidine 129, 179 17 Ancylostoma braziliensis 163,184 21 Aminotetralin derivatives 429 18 Ancylostoma braziliensis 199 17 5-Amino-v-triazole-4-carboxamide 336 17 Ancylostoma caninum 160 22 4-Aminotwistanes 280 18 Ancylostoma caninum 199 236 Index
Recommended publications
  • The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans

    The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans

    >+'è ,'i5 1. The Disposition of Morphine and its 3- and 6- Glucuronide Metabolites in Humans and Sheep A Thesis submitted in Fulfilment of the Requirements for the Degree of Doctor of Philosophy in Science at the University of Adelaide Robert W. Milne B.Pharm.(Hons), M.Sc. Department of Clinical and Experimental Pharmacology University of Adelaide August 1994 Ar,-,..u i.'..t itttlí I Corrigenda Page 4 The paragraph at the top of the page should be relocated to inimediatèly follow the section heading "1.2 Chemistry" on page 3" Page 42 (lines 2,5 and/) "a1-acid glycoProtein" should read "cr1-acid glycoprotein". Page 90 In the footnote "Amoxicillin" and "Haemacell" should read "Amoxycillin" and "Haemaccel", respectively. Page I 13 (tine -l l) "supernate!' should read "supernatant". ' '(j- Page I 15 (line -9) "supernate" should read "supernatalït1-. Page 135 To the unfinished sentence at the bottom of the page should be added "appears to be responsible for the formation of M3G, but its relative importance remains unknown. It was also proposed that morphine is involved in an enterohepatic cycle." Page 144 Add "Both infusions ceased at 6 hr" to the legend to Figure 6.3. Page 195 (line 2) "was" should fead "were". Page 198 (line l3) "ro re-€xamine" should read "to te-examine". Pages 245 to29l Bibliosraohv: "8r.." should read "Br.". For the reference by Bhargava et aI. (1991), "J. Pharmacol.Exp.Ther." should read "J. Pharmacol. Exp. Ther." For the reference by Chapman et aI. (1984), a full-stop should appear after"Biomed" . For the reference by Murphey et aI.
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension

    Dopamine: a Role in the Pathogenesis and Treatment of Hypertension

    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • Anti-Cholinergic Alkaloids As Potential Therapeutic Agents for Alzheimer's Disease

    Anti-Cholinergic Alkaloids As Potential Therapeutic Agents for Alzheimer's Disease

    Indian Journal of Biochemistry & Biophysics Vol. 50, April 2013, pp. 120-125 Anti-cholinergic alkaloids as potential therapeutic agents for Alzheimer’s disease: An in silico approach Huma Naaz, Swati Singh, Veda P Pandey, Priyanka Singh and Upendra N Dwivedi* Bioinformatics Infrastructure Facility, Center of Excellence in Bioinformatics, Department of Biochemistry, University of Lucknow, Lucknow 226 007, India Received 10 September 2012; revised 25 January 2013 Alzheimer’s disease (AD), a progressive neurodegenerative disorder with many cognitive and neuropsychiatric symptoms is biochemically characterized by a significant decrease in the brain neurotransmitter acetylcholine (ACh). Plant-derived metabolites, including alkaloids have been reported to possess neuroprotective properties and are considered to be safe, thus have potential for developing effective therapeutic molecules for neurological disorders, such as AD. Therefore, in the present study, thirteen plant-derived alkaloids, namely pleiocarpine, kopsinine, pleiocarpamine (from Pleiocarpa mutica, family: Annonaceae), oliveroline, noroliveroline, liridonine, isooncodine, polyfothine, darienine (from Polyalthia longifolia, family: Apocynaceae) and eburnamine, eburnamonine, eburnamenine and geissoschizol (from Hunteria zeylanica, family: Apocynaceae) were analyzed for their anti-cholinergic action through docking with acetylcholinesterase (AChE) as target. Among the alkaloids, pleiocarpine showed promising anti-cholinergic potential, while its amino derivative showed about six-fold
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares

    Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares

    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
  • 33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline And

    33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline And

    J. Smooth Muscle Res. 33 : 99-106. 99 The )32 and [33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline and Salbutamol in Guinea Pig Taenia Caecum Katsuo KOIKE, Tsukasa IcHiNo, Takahiro HORINOUCHI and Issei TAKAYANAGI Departmentof Chemical Pharmacology, Toho University School of PharmaceuticalSciences, 2-2-1, Miyama,Funabashi, Chiba 274, Japan Abstract To understand the receptor subtypes responsible for /3adrenoceptormediated relaxa tion of guinea pig taenia caecum, we investigated the effects of isoprenaline and salbutamol . Isoprenaline and salbutamol caused dose-dependent relaxation of the guinea pig taenia caecum. Propranolol, bupranolol and butoxamine produced shifts of the concentration response curves for isoprenaline and salbutamol. Schild regression analyses carried out for propranolol against isoprenaline and salbutamol gave pA2 values of 8.43 and 8.88, respective ly. Schild regression analyses carried out for butoxamine against isoprenaline and sal butamol gave pA2 values of 6.46 and 6.68, respectively. Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 8.60 and 8.69, respectively. However, in the presence of 3 x 10' M atenolol, 10-4 M butoxamine and 10-6 M phentolamine to block the fir , /32 and a -adrenoceptor effects, respectively, Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 5.77 and 5.97, respectively. These results suggest that the relaxant responses to isoprenaline and salbutamol in the guinea pig taenia caecum are mediated by both the /.32 and the A-adrenoceptors. Key words : f2-adrenoceptor, A-adrenoceptor, isoprenaline, salbutamol , guinea pig taenia caecum Introduction The /3adrenoceptors were subclassified as and /32subtypes based on the agonist potency and tissue localization.
  • Wo 2010/075090 A2

    Wo 2010/075090 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
  • United States Patent (19) (11) 4,232,002 Nogrady 45) Nov

    United States Patent (19) (11) 4,232,002 Nogrady 45) Nov

    United States Patent (19) (11) 4,232,002 Nogrady 45) Nov. 4, 1980 (54) PROCEDURES AND PHARMACEUTICAL (56) References Cited PRODUCTS FOR USE IN THE PUBLICATIONS ADMINISTRATION OF ANTHISTAMINES American Hospital Formulary Service, 1966, 4:00 Anti (75. Inventor: Stephen G. Nogrady, Sully, near histamine Drugs, Penarth, Great Britain Primary Examiner-Stanley J. Friedman Attorney, Agent, or Firm-Young & Thompson 73) Assignee: The Welsh National School of Medicine, Penarth, Great Britain 57 ABSTRACT An antihistamine of the benzhydrylether, alkylamine, or (21) Appl. No.: 965,171 benzocyloheptatiophene class is suitable for use in the therapeutic treatment or prophylaxis of reversible air (22 Filed: Nov.30, 1978 ways obstruction by inhalation. The antihistamine may be clemastine, chlorpheniramine or ketotifen and may (30) Foreign Application Priority Data be in the form of a composition in admixture with a diluent. The antihistamine can be administered from a Dec. 1, 1977 GB) United Kingdom ..................... 5.0020 pharmaceutical inhalation device which is designed to 51 Int. Cl. ......................... A61L 9/04; A61 K9/04; administer a dosage unit of the antihistamine. The inha A61K 31/44 lation device can be in the form of a pressurized aerosol 52 U.S. C. ........................................ 424/45; 424/46; inhaler or a dry powder insufflator. 424/263 58) Field of Search ............................ 424/263, 46, 45 5 Claims, No Drawings 4,232,002 1. 2 inhalation provides the equivalent of 0.1 to 5 mg. of PROCEDURES AND PHARMACEUTICAL clemastine, or 0.05 to 2.5 mg. of chlorpheniramine. The PRODUCTS FOR USE IN THE ADMINISTRATION drug may be inhaled in the form of a mist or nebulized OF ANTHISTAMINES spray, or as a cloud of fine solid particles, and may be inhaled from a variety of inhaler devices.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).